Gene: IPP

3652
KLHL27
intracisternal A particle-promoted polypeptide
protein-coding
1p34.1
Ensembl:ENSG00000197429 MIM:147485 Vega:OTTHUMG00000008004 UniprotKB:Q9Y573
NC_000001.11
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.388e-1 (AD)  8.388e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NT5C20.827
RBL20.805
SBF20.774
ASXL20.771
ENTPD50.771
AQR0.769
DBT0.762
NEK10.762
GSTCD0.758
APH1B0.757

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.384
OR4F29-0.382
WFIKKN1-0.342
NPW-0.338
UTF1-0.308
KCNG2-0.286
ANP32C-0.285
EPPIN-0.281
NANOS2-0.278
CELSR1-0.278

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of IPP mRNA"21346803
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of IPP mRNA"21346803
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of IPP mRNA17562736
C006780bisphenol Abisphenol A results in decreased expression of IPP mRNA26063408
C006780bisphenol Abisphenol A results in increased methylation of IPP promoter27312807
C006780bisphenol Abisphenol A results in decreased expression of IPP mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of IPP mRNA26079696
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of IPP mRNA20938992
D019327Copper SulfateCopper Sulfate results in decreased expression of IPP mRNA19549813
C030973cupric oxidecupric oxide results in decreased expression of IPP mRNA22077320
D016572CyclosporineCyclosporine results in decreased expression of IPP mRNA20106945
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of IPP mRNA27392435
D002945CisplatinCisplatin results in increased expression of IPP mRNA27392435
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of IPP mRNA29097150
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in increased expression of IPP mRNA23649840
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of IPP mRNA20938992
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased expression of IPP mRNA18951874
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of IPP mRNA27392435
C045463leflunomideleflunomide results in decreased expression of IPP mRNA28988120
D008627Mercuric ChlorideMercuric Chloride results in decreased expression of IPP mRNA16507785
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of IPP mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of IPP mRNA28001369
D008767Methylmercury CompoundsMethylmercury Compounds results in decreased expression of IPP mRNA27544571
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of IPP mRNA23649840
D009532NickelNickel results in decreased expression of IPP mRNA25583101
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of IPP mRNA25729387
C030110oxaliplatinoxaliplatin results in decreased expression of IPP mRNA25729387
D010433PentylenetetrazolePentylenetetrazole affects the expression of IPP mRNA21503142
D010634PhenobarbitalPhenobarbital results in decreased expression of IPP mRNA21896655
D010672PhenytoinPhenytoin results in increased expression of IPP mRNA20345932
D010936Plant ExtractsPlant Extracts results in increased expression of IPP mRNA23557933
D012822Silicon DioxideSilicon Dioxide results in decreased expression of IPP mRNA25351596
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of IPP mRNA21570461
D013792ThalidomideThalidomide results in decreased expression of IPP mRNA26217789
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of IPP mRNA25729387
D019772TopotecanTopotecan results in decreased expression of IPP mRNA25729387
D014241TrichloroethyleneTrichloroethylene results in increased methylation of IPP gene27618143
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA"27188386
C012589trichostatin Atrichostatin A affects the expression of IPP mRNA28542535
C012589trichostatin Atrichostatin A results in decreased expression of IPP mRNA24935251|2627250
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of IPP mRNA19042947
D014520UrethaneUrethane results in decreased expression of IPP mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IPP mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of IPP mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of IPP mRNA23179753|2627250
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of IPP gene25560391
D014810Vitamin EVitamin E results in decreased expression of IPP mRNA19244175

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003779actin binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0016567protein ubiquitination-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IEA-  
GO:0015629actin cytoskeleton-TAS10072760  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21951516Predicting erectile dysfunction following surgical correction of Peyronie's disease without inflatable penile prosthesis placement: vascular assessment and preoperative risk factors. (2012 Jan)Taylor FLJ Sex Med